에 대한 최신 뉴스 Aurora Cannabis (NASDAQ:ACB) 주식

Aurora Cannabis

Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements.

Stocks Photo by WHYFRAME on Shutterstock

Equities

News

Markets

AMZN

PARA

TSLA

수요일 거래 종료 시점에서 다우존스 산업평균지수는 0.1% 하락한 39,127.14로, S&amp;P 500 지수는 5,211.49까지 상승한 것으로 나타났습니다. 마찬가지로 나스닥 지수도 0.2% 상승하여 16,227.46으로 마감했습니다.



이들은 소매 트레이더들과 투자자들의 관심을 끈 주요 주식입니다.



Amazon.com Inc.(NASDAQ:AMZN)



Amazon의

아마존, 디즈니, 오로라 카나비스, 파라마운트 글로벌, 테슬라:  오늘 투자자들의 관심을 받고 있는가?

Aurora Cannabis Inc

Ace Global Business Acquisition Ltd

Ace Global Business Acquisition Ltd Units (1 Ord & 1 War)

Ace Global Business Acquisition Ltd Warrants (26/03/2026)

ALBINA COMMUNITY BNCRP by Albina Community Bancorp

Annabidiol Corp

ARCO BIOMEDICAL CO LTD by Acro Biomedical Co., Ltd.

Acro Biomedical Co Ltd

Scotiabank maintains i-80 Gold (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IAUX#AMEX">IAUX</a>) with a Sector Outperform and lowers the price target from $2.25 to $1.5.

Price Target

Analyst Ratings

IAUX

Scotiabank Maintains Sector Outperform on i-80 Gold, Lowers Price Target to $1.5

<a href="https://www.bloomberg.com/news/articles/2025-06-02/musk-s-xai-launches-5-billion-debt-sale-through-morgan-stanley" title="https://www.bloomberg.com/news/articles/2025-06-02/musk-s-xai-launches-5-billion-debt-sale-through-morgan-stanley">https://www.bloomberg.com/news/articles/2025-06-02/musk-s-xai-launches-5-billion-debt-sale-through-morgan-stanley</a>

GOOG

GOOGL

MSFT

'Musk's xAI Launches $5 Billion Debt Sale Through Morgan Stanley' - Bloomberg News

Zscaler Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) shares are trading higher Monday on what appears to be continued momentum after the company posted better-than-expected fiscal third-quarter earnings and raised its <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45700639/zscaler-stock-is-gaining-friday-whats-going-on">full-year guidance last week</a>.
What To Know: The cybersecurity firm reported adjusted earnings of 84 cents per share, beating analyst estimates of 75 cents per share and revenue of $678 million, which topped consensus forecasts of $666.86 million.
The results were driven by demand for Zscaler&#8217;s Zero Trust Exchange platform and increased customer adoption across its portfolio. Calculated billings climbed 26% year-over-year to $785 million, exceeding expectations. Annual recurring revenue (ARR) also grew 23% year-over-year to $2.9 billion.
Despite the positive results, Piper Sandler downgraded the stock to Neutral from Overweight, citing valuation concerns and potential risks tied to Zscaler&#8217;s recent Red Canary acquisition and federal sector uncertainty. Still, the firm raised its price target from $235 to $260.
Other analysts were more bullish. RBC, KeyBanc, Needham and Rosenblatt all increased their price targets, with Rosenblatt pushing its forecast to $315. Analysts highlighted Zscaler&#8217;s strong execution, growing momentum in key product areas like Zero Trust and AI-driven security and improving sales productivity. Several firms also noted the company did not report any negative impact from current tariffs, a positive sign in the current macro environment. Positive analyst changes continue to roll in this week with Canaccord Genuity lifting its target from $230 to $305.
Zscaler's management raised full-year 2025 revenue guidance to a range of $2.659 billion to $2.661 billion, slightly above analyst estimates. Full-year adjusted earnings are now expected to be between $3.18 and $3.19 per share, up from prior forecasts and well ahead of the Street&#8217;s $3.07 estimate.
ZS Price Action: Zscaler shares were up 5.89% at $291.94 at the time of writing. Zscaler shares are now up more than 61% year-to-date. The stock climbed to new 52-week highs on Monday, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/economic-data/25/06/45724821/trumps-manufacturing-narrative-weakens-as-may-data-shows-sharper-contraction-stubborn-inflation">Trump&#8217;s Manufacturing Narrative Weakens As May Data Shows Sharper Contraction, Stubborn Inflation </a></li>
</ul>
Image via Shutterstock.

Movers

Zscaler Shares Hit New 52-Week High: What's Driving The Momentum?

<ul class="wp-block-list">
<li>The U.S. has the largest number of high-net-worth individuals, according to a new report from Henley &amp; Partners and New World Health</li>
<li>37% of the global millionaire population, 36% of the world's centimillionaires, and 33% of billionaires call the country home</li>
<li>These ultra-wealthy individuals primarily live in or near major cities like New York, San Francisco, and Los Angeles</li>
</ul>
The U.S. is home to 37% of the global millionaire total, according to a new report from Henley &amp; Partners and New World Wealth.
The <a href="https://www.henleyglobal.com/newsroom/press-releases/usa-wealth-report-2025">USA Wealth Report</a> says that over 6 million high net worth individuals, defined as those with investable assets of $1 million or more, resided in the U.S. at the end of 2024. Additionally, 36% of the world's centimillionaires and 33% of the world's billionaires also call the country home.
Don't Miss:
<ul class="wp-block-list">
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
<li>Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>. </li>
</ul>
Over the past decade, the U.S. has seen its millionaire population increase by 78%. This growth slightly outpaces China, which saw its millionaire population increase by 74% between 2014 and 2024, and well outpaces other wealthy countries like Japan (5%), Canada (26%), Switzerland (28%), and the UK (-9%).&nbsp;
Tim Klatte, partner at Grant Thornton China, warns high net worth individuals that despite this incredible growth rate, they shouldn't get too comfortable. "The U.S.–China trade war is more than an economic battle — it is a complex geopolitical contest with far-reaching consequences," he said in a statement accompanying the report. "HNW investors must account for the risk of escalating tensions, potential breakdowns in trade negotiations, and the broader threat of international conflict. These geopolitical dynamics can significantly influence investment decisions, asset allocation, and long-term wealth preservation."
Trending: Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.
In fact, this economic unrest has led many ultra-wealthy Americans to explore their options when it comes to moving their wealth outside the US. According to the report, US citizens account for over 30% of all investment migration applications submitted through Henley &amp; Partners at this point in the year. A number that is nearly double the combined total of the next five investor nationalities, which include Turkish, Indian, and British.
"We're witnessing a new level of sophistication in how affluent Americans manage and diversify their wealth," says Basil Mohr-Elzeki, managing partner at Henley &amp; Partners North America. "Securing alternative residences and citizenships is now a strategic form of risk management — a thoughtful ‘Plan B' that enhances family resilience, unlocks global opportunities, and safeguards multigenerational legacies."
See Also: <a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a>
Within the U.S., high net worth individuals tend to congregate in areas the report calls "urban wealth hubs." New York City has the highest number of high net worth individuals, with 384,500 millionaires, 818 centimillionaires, and 66 billionaires. The San Francisco Bay Area, which includes Silicon Valley, is second with 342,400 millionaires, 756 centimillionaires, and 82 billionaires. Los Angeles, Chicago, and Dallas round out the top five.
"Despite a wave of policy changes and their subsequent implications around the world, the relative political stability, rule of law, economic prospects, culture of innovation, not to mention the US dollar remaining the global reserve currency, have squarely positioned the USA as an environment in which to do business and to invest," said David K. Young, president at the Committee for Economic Development of The Conference Board in a statement accompanying the report.
Read Next: <a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.
Image: Shutterstock

Personal Finance

37% Of The World's Millionaires Call The US Home, Up 78% Over The Last Decade

WIIM

RIVN

Rivian Automotive shares are trading lower after the company announced a proposed $1.25 billion senior secured green notes offering.

Scotiabank analyst Louise Chen downgrades Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) from Sector Outperform to Sector Perform and announces $135 price target.

Downgrades

BPMC

Scotiabank Downgrades Blueprint Medicines to Sector Perform, Announces $135 Price Target

CGAU

RGLD

SSRM

USAU

Shares of precious metals stocks are trading higher as gold and silver prices rise amid dollar weakness.

JP Morgan analyst Brian Cheng downgrades Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) from Overweight to Neutral and lowers the price target from $130 to $129.

JP Morgan Downgrades Blueprint Medicines to Neutral, Lowers Price Target to $129

<a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44300120/binance-ceo-richard-teng-hails-donald-trumps-bitcoin-reserve-xrp-ethereum-solana-digital-asset-stockpile">Binance CEO Richard Teng</a> on Monday said the United States is &#8220;firmly back in the driver's seat&#8221; to lead the global crypto industry, following a major regulatory development that saw U.S. authorities drop a lawsuit against the crypto exchange and its founder Changpeng Zhao.
What Happened: "This is a significant win not just for Binance, but for the entire industry," Teng said during an <a href="https://www.cnbc.com/video/2025/06/02/binance-ceo-richard-teng-on-sec-suit-dismissal-trump-meme-coin-and-crypto-regulation.html?__source=sharebar&#x7C;twitter&amp;par=sharebar">interview</a> with CNBC. "The U.S. is firmly back in the driver's seat to become the crypto hub of the world."
Teng credited the shift to the regulatory approach taken by the current administration, praising what he called a "considerate and thoughtful" stance that favors regulatory clarity over enforcement-first tactics.
The CFTC's original complaint had accused Binance of allowing illegal access to U.S. users, inflating trading volumes, and co-mingling customer funds. 
Its dismissal now marks a turning point in the broader U.S. regulatory landscape, according to the CEO.
Looking ahead, Teng expressed optimism about bipartisan efforts to create clear rules for the industry, stating that greater clarity will benefit investors, companies and regulators alike.
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45718017/nothing-stops-this-train-us-fiscal-deficits-drive-bitcoins-case-as-a-hedge-says-lyn-alden">&#8216;Nothing Stops This Train&#8217;: US Fiscal Deficits Drive Bitcoin&#8217;s Case As A Hedge, Says Lyn Alden</a>
"We are deeply supportive of a regulatory framework that protects users," he said, citing Binance's milestone of surpassing 275 million global users.
Teng also addressed concerns over the proliferation of meme coins tied to political figures like President Donald Trump. 
While avoiding direct comment on their legitimacy, Teng emphasized the decentralized and permissionless nature of token creation in crypto.
Beyond the legal developments, Teng highlighted Binance's growing compliance infrastructure. 
The platform now employs over 1,400 people in its compliance division and is regulated in more than 22 countries.
"We are the most regulated global platform today," Teng said. "Our focus is on security, compliance, and user protection."
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/05/45708417/110m-wiped-out-bitcoin-whale-trader-gets-burned-as-btc-tags-104-150">$110M Wiped Out: Bitcoin Whale Trader Gets Burned As BTC Tags $104,150</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

US Is Poised To Become Global Crypto Hub After Regulatory Breakthrough, Binance CEO Says

Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) shares are trading higher Monday after the company announced its new COVID-19 vaccine secured clearance from the U.S. Food and Drug Administration (FDA) for seniors and <a href="https://www.benzinga.com//node/45708511">at-risk individuals.</a>
What To Know: In a Phase 3 clinical trial, the new vaccine, mNEXSPIKE, showed a higher vaccine efficacy as well as a similar safety profile compared to the company&#8217;s original COVID-19 vaccine. 
&#8220;The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19,&#8221; said Stéphane Bancel, CEO of Moderna.
&#8220;COVID-19 remains a serious public health threat, with more than 47,000 Americans dying from the virus last year alone. We appreciate the FDA&#8217;s timely review and thank the entire Moderna team for their hard work and continued commitment to public health.&#8221;
Moderna expects to have mNEXSPIKE available for eligible populations in the U.S. for the 2025-2026 respiratory virus season. The new vaccine is under review with regulators in multiple markets around the world.
See Also: <a href="https://www.benzinga.com/news/25/06/45727221/vera-therapeutics-applied-digital-kymera-therapeutics-and-other-big-stocks-moving-higher-on-monday">Vera Therapeutics, Applied Digital, Kymera Therapeutics And Other Big Stocks Moving Higher On Monday</a>
MRNA Price Action: At the time of writing, Moderna stock is trading 2.73% higher at $27.28, according to data from <a href="https://pro.benzinga.com/">Benzinga Pro.</a>
Image: Shutterstock.

MRNA

Moderna Stock Is Trading Higher Monday: What's Going On?

As crypto adoption continues to grow, how individuals trade, not what they trade, has become the focus. While centralized platforms remain popular for convenience, they expose traders to more risk than is necessary.
More investors are looking for how to maintain full control of their crypto assets while minimizing exposure to third parties. One solution is necessary, decentralized crypto swaps, for example exchanging BTC for USDT. &nbsp;&nbsp;
The Problem with Centralized Swap Brokers
Most wallet-based swap interfaces, software or hardware, use centralized intermediary brokers to process transactions at present.
While the services are quick and convenient, they also expose:
• Counterparty risk, Funds are in the control of a third party temporarily during the swap.
• Privacy trade-offs, KYC requirements can force users to reveal sensitive personal information.
• Higher fees and slippage, Centralized services are more costly than decentralized alternatives.
For security-minded traders and long-term investors, these compromises are becoming ever harder to make.
Why Decentralized Swaps Offer a Better Alternative
Protocols that facilitate decentralized trading infrastructure, and wallet-to-wallet transactions without surrendering custody or personal data are the future.
Such solutions should also:
• Reduce reliance on any one central authority,
• Improve fee transparency and access to greater liquidity,
• More accurately reflect the underlying basis of crypto, decentralization and user sovereignty
Other wallet providers are beginning to recognize the value of natively embedding such decentralized protocols on their platforms, and user demand is only growing.
A Quantum Threat to Security Is on the Horizon
In addition to swap risk, another long-term problem is now taking shape, quantum computing.
Some experts, including venture capitalist Chamath Palihapitiya, are sounding the alarm that quantum developments can arrive as soon as 5 to 10 years from now, with the potential to break the encryption that safeguards today&#8217;s digital assets.
While it remains one of the most secure ways to hold crypto, exposure during swaps, especially with third parties, could be an entry point of vulnerability in the future.
Security-aware users are already adopting best practices such as:
• Never using the same exact address for multiple transactions. Use a wallet that generates a new one each time.
• Minimizing exposure to third-party custodians,
• Utilizing wallets and protocols that support decentralized infrastructure
As quantum abilities reach maturity, decentralization will not just enhance privacy and autonomy but may also turn into a default line of defense.
The Bottom Line
Integrating decentralized swap protocols into wallet ecosystems isn&#8217;t just a UX enhancement, it&#8217;s a long-term move towards privacy, affordability, and improved personal security.
For cryptocurrency traders wanting to stay ahead of both market risk and technological developments, solutions that adopt underlying decentralized principles are more important than ever.
The author has an investment in BTC.
&#x2A;&#x2A;
We at <a href="https://cryptoflowzone.com/">https://cryptoflowzone.com/</a> will continue to monitor and evaluate developments in this space to help traders make the correct choices. We also expect to pressure cold wallet providers to develop decentralized swap protocols within their solution, and offer investors a safer way of broadcast transacting in the future. Keep your eyes on the prize and Trade safe.

Opinion

Why Decentralized Swaps Are The Next Frontier For Secure Crypto Trading

Piper Sandler analyst Paul Newsome initiated coverage on Aspen Insurance Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHL#NYSE">AHL</a>) with an Overweight rating and <a href="https://www.benzinga.com/quote/ahl/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $40</a>.
The company&#8217;s IPO took place on May 8 on the NYSE exchange and it offered shares at a price of $30 per share with an insider lock-up period of 180 days<a href="https://www.benzinga.com//node/45329236" target="_blank" rel="noreferrer noopener"> that ends on November 04, 2025</a>.
The analyst writes that AHL is a reasonably profitable specialty insurer and reinsurer and he anticipates a recently completed business transformation to facilitate future growth and improved profitability.
Newsome notes that the company underwent a significant restructuring following its acquisition by Apollo in 2019.
The analyst adds that despite divesting approximately 17 business lines across its insurance and reinsurance segments, the company has reported notable improvements in its underwriting profitability and Gross Written Premium (GWP) growth.
The analyst highlights that this transformation has reduced volatility in its underwriting performance. Also, operating Return on Equity (ROE) reached 19.4% in 2024, with a three-year average of 17.1%.
Moreover, the company has seen substantial gains in underwriting profitability, and the combined ratio improved from 98.8% in 2021 to 88.0% in 2024, according to the analyst.
Newsome says that this enhanced underwriting performance is primarily attributed to a reduction in the expense ratio, an improving underlying loss ratio, and better management of catastrophe loss risks.
Overall, the analyst believes that the company warrants a slight premium valuation compared to its reinsurance peer group, given that its specialty business accounts for approximately 60% of its gross written premiums.
The analyst estimates the EPS of $3.61 for FY25 and $4.97 for FY26.
Price Action: AHL shares are up 0.81% at $34.69  at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com//node/45196561" target="_blank" rel="noreferrer noopener">Loews Posts Mixed&nbsp;Q1&nbsp;Results: Pipeline Strength Offsets Insurance And Hotel Weakness</a></li>
</ul>
Photo: Shutterstock

Initiation

Aspen Insurance Emerges From Turnaround With Momentum: Analyst Sees More Upside Ahead

<a href="https://www.chicagofed.org/publications/speeches/2025/june-2-quad-cities-business-journal" title="https://www.chicagofed.org/publications/speeches/2025/june-2-quad-cities-business-journal">https://www.chicagofed.org/publications/speeches/2025/june-2-quad-cities-business-journal</a>

Macro Economic Events

Economics

Federal Reserve

Fed's Goolsbee Says Recent PCE Inflation Print May Have Been 'Last Vestige' Of Pre-Tariff Impact

Oppenheimer analyst Andreas Argyrides assumes Harmony Biosciences Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRMY#NASDAQ">HRMY</a>) with a Outperform rating and announces Price Target of $61.

HRMY

Oppenheimer Assumes Harmony Biosciences Hldgs at Outperform, Announces Price Target of $61

AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) on Monday released results from <a href="https://www.benzinga.com/general/health-care">three Phase 3 clinical trials</a> at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting: DESTINY-Breast09, MATTERHORN, and SERENA-6.
In the DESTINY-Breast09 trial, Enhertu (trastuzumab deruxtecan) combined with pertuzumab was evaluated as a first-line treatment for HER2-positive metastatic breast cancer, compared to a standard regimen of a taxane, trastuzumab, and pertuzumab (THP). 
Topline data <a href="https://www.benzinga.com/general/biotech/25/04/44894989/astrazeneca-daiichi-sankyos-multi-billion-dollar-cancer-drug-shows-superior-efficacy-across-broad" target="_blank" rel="noreferrer noopener">were shared in April</a>.
Also Read: <a href="https://www.benzinga.com/general/biotech/25/05/45168310/astrazenecas-triple-combination-therapy-breztri-hits-primary-goals-in-two-pivotal-studies-for-asthma" target="_blank" rel="noreferrer noopener">AstraZeneca&#8217;s Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma</a>
Results indicated that the <a href="https://www.astrazeneca.com/media-centre/press-releases/2025/enhertu-plus-pertuzumab-reduced-the-risk-of-disease-progression-or-death-vs-thp-as-1st-line-therapy-in-patients-with-her2-positive-metastatic-breast-cancer.html">Enhertu</a> combination reduced the risk of disease progression or death by 44%. Median progression-free survival (PFS) reached 40.7 months with the Enhertu regimen versus 26.9 months for THP, a benefit observed across patient subgroups.
Investigator-assessed median PFS was 40.7 months for the Enhertu arm and 20.7 months for THP. The confirmed objective response rate was 85.1% for the Enhertu combination and 78.6% for THP, with 58 complete responses in the Enhertu group compared to 33 with THP. 
The median duration of response was 39.2 months for the Enhertu combination and 26.4 months for THP. Overall survival data was not yet mature, though an early trend favored the Enhertu combination.
The MATTERHORN trial assessed <a href="http://astrazeneca-us.com/media/press-releases/2025/IMFINZI-durvalumab-regimen-reduced-risk-of-progression-recurrence-or-death-by-29-percent-in-early-stage-gastric-cancer-vs-chemotherapy-alone-in-MATTERHORN-Phase-III-trial.html?utm_source=external-comms&amp;utm_medium=memo&amp;utm_campaign=asco2025&amp;utm_term=corporate&amp;utm_content=matterhorn">Imfinzi</a> (durvalumab) with standard FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) chemotherapy as a perioperative treatment for resectable, early-stage, and locally advanced gastric and gastroesophageal junction (GEJ) cancers, compared to chemotherapy alone.
Topline data <a href="https://www.benzinga.com/general/biotech/25/03/44188407/astrazenecas-imfinzi-based-regimen-shows-improved-event-free-survival-in-early-stage-gastric-canc" target="_blank" rel="noreferrer noopener">were released in March</a>.
A planned interim analysis showed that the Imfinzi-based regimen led to a 29% reduction in the risk of disease progression, recurrence, or death. 
Median event-free survival (EFS) was not reached in the Imfinzi arm, compared to 32.8 months in the chemotherapy-alone arm. The estimated 24-month EFS rate was 67.4% for the Imfinzi regimen and 58.5% for chemotherapy alone. 
A trend towards improved overall survival was noted for the Imfinzi-based regimen, with formal assessment to follow.
The SERENA-6 trial investigated <a href="https://www.astrazeneca-us.com/media/press-releases/2025/Camizestrant-reduced-the-risk-of-disease-progression-or-death-by-56-in-patients-with-advanced-HR-positive-breast-cancer-with-an-emergent-ESR1-tumor-mutation-in-SERENA-6-Phase-III-trial.html?utm_source=external-comms&amp;utm_medium=memo&amp;utm_campaign=asco2025&amp;utm_term=corporate&amp;utm_content=serena-6">camizestrant</a> combined with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) in patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer whose tumors developed an ESR1 mutation during first-line treatment with an aromatase inhibitor (AI) and a CDK4/6 inhibitor.
Topline data were <a href="https://www.benzinga.com/25/02/43975577/astrazenecas-investigational-cancer-drug-shows-first-line-benefit-in-combination-with-widely-cancer-medicines" target="_blank" rel="noreferrer noopener">shared in February</a>.
The trial compared switching to the camizestrant combination against continuing the AI plus CDK4/6 inhibitor. The camizestrant combination reduced the risk of disease progression or death by 56%. 
Median PFS was 16.0 months for patients who switched, versus 9.2 months for those continuing the AI combination. The median time to deterioration of global health status was 23.0 months for the camizestrant arm and 6.4 months for the AI combination arm. 
While data for time to second disease progression and overall survival were immature, a trend favored the camizestrant combination for PFS2.
Price Action: AZN stock is trading lower by 0.95% at $72.14 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45726872/regeneron-experimental-weight-loss-drug-with-novo-nordisks-wegovy-helps-preserve-lean-mass-in-mid-stage-study" target="_blank" rel="noreferrer noopener">Regeneron&#8217;s Obesity Trial With Novo Nordisk&#8217;s Wegovy Hits Lean Target</a></li>
</ul>
Photo by Piotr Swat Shutterstock

Biotech

Large Cap

Health Care

General

AstraZeneca Highlights Significant Gains Across Three Major Cancer Trials At ASCO

Meta Platforms shares are trading higher amid reports that the company is planning to fully automate making of ads using AI.

Oppenheimer analyst Andreas Argyrides assumes Aquestive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQST#NASDAQ">AQST</a>) with a Outperform rating and lowers Price Target of $7.

AQST

Oppenheimer Assumes Aquestive Therapeutics at Outperform, Lowers Price Target of $7

Shares of Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) are trading lower Monday as the company faces growing pressure from Chinese electric vehicle competitors, which posted strong <a href="https://www.benzinga.com/markets/eurozone/25/05/45616006/teslas-european-woes-see-no-end-april-sales-crash-49-as-rivals-race-ahead-in-ev-market">delivery numbers for May</a>.
What To Know: Tesla&#8217;s rivals, BYD, Li Auto, Nio and Xpeng, saw <a href="https://www.benzinga.com/news/topics/25/06/45716179/teslas-china-sales-slump-while-byd-and-li-auto-post-strong-gains-report">sales growth in China</a> last month. Li Auto reported a 17% month-over-month increase, delivering 40,856 vehicles. Nio followed with over 33,500 deliveries and Xpeng delivered more than 23,000 units. BYD led the group with 204,369 battery electric vehicle deliveries in May, representing a 40% year-over-year increase.
Meanwhile Tesla has battled declining sales in the region after reporting roughly 58,000 vehicle sales in China in April, including exports. The company&#8217;s sales in the first eight weeks of second quarter have declined 23% year-over-year, suggesting continued softness in its second-largest market. Despite improving registration numbers in May — over 11,000 units registered in China for two consecutive weeks — the broader trend remains negative.
Tesla&#8217;s challenges extend beyond China. In Europe, the company posted a steep 49% drop in sales for April. For the first time, BYD surpassed Tesla in the region, signaling a significant shift in EV market dynamics.
Investors are watching closely as Tesla approaches its June 12 Robotaxi unveiling in Austin, a potential catalyst for the EV stock. 
Tesla CEO Elon Musk said last month that all that matters for the company long term are autonomy and the company's Optimus bots, which are expected to &#8220;overwhelmingly dominate the future financial success of the company.&#8221;
Analysts remain cautiously optimistic given Tesla&#8217;s advancements in Full Self-Driving (FSD) technology. However, questions linger about the company&#8217;s ability to maintain competitive footing amid rising global competition and aggressive pricing strategies, especially in China.
Despite the concerns about sales, Tesla shares have climbed about 20% over the past month as Musk&#8217;s time as a <a href="https://www.benzinga.com/25/05/45668119/tesla-rides-a-bullish-wave-as-byd-slashes-prices-whos-really-winning-the-ev-war" target="_blank" rel="noreferrer noopener">special government employee</a> comes to a close. Musk joined the Trump administration earlier this year to take a lead role at the Department of Government Efficiency, or DOGE. He announced that he was <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45672177/whats-going-on-with-tesla-stock-thursday">officially stepping away</a> from the position last week.
TSLA Price Action: Tesla shares were down 2.59% at $337.47 at the time of publication Monday, according to<a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"> Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/economic-data/25/06/45724821/trumps-manufacturing-narrative-weakens-as-may-data-shows-sharper-contraction-stubborn-inflation">Trump&#8217;s Manufacturing Narrative Weakens As May Data Shows Sharper Contraction, Stubborn Inflation </a></li>
</ul>
Image via Shutterstock.

Tesla Stock Is Trading Lower Today: What's Going On?

Gold is trading higher amid dollar weakness and trade policy uncertainty.

Fed's Goolsbee Says Still Think Underneath All The Tariff 'Dirt In The Air,' Rates Can Come Down Over 12-18 Months; Still Think If We Can Get Past This Bumpy Period, Dual Mandate Looks Pretty Good; A Little Gun-Shy About Arguing That Tariffs Will Have A Transitory Effect On Inflation

Press Releases

Aurora Cannabis Expands Medical Cannabis Pastille Offerings in Australia

Aurora Cannabis Announces Breakthrough Discovery of Powdery Mildew Resistant Cultivars

Aurora Cannabis to Speak at the Global Cannabis Regulatory Summit

Aurora Cannabis Recognized for Executive Gender Diversity by The Globe and Mail

Aurora Cannabis Introduces the Company's First Inhalable Resin Cartridges for Patients in the United Kingdom

International Star Inc Announces New Engagement of T Bone Capital

Aurora Cannabis Announces the Completion of a Multimillion Dollar Investment and Renaming of B.C. Manufacturing Facility

Fintech

Exec Edge Launches Research Coverage with Initiation Notes on FLD, CLYM, STKS, REX, ACB

Management

Rubicon Organics Announces Appointment of Glen Ibbott as Interim CFO

Aurora to Participate in TD Cowen's 9th Annual Future of the Consumer Conference

CLYM

ILST

ROMJF

STKS

TSX:ACB

TSXV:ROMJ

CIBC

Canaccord Genuity

Piper Sandler

수요일 거래 종료 시점에서 다우존스 산업평균지수는 0.1% 하락한 39,127.14로, S&amp;P 500 지수는 5,211.49까지 상승한 것으로 나타났다. 마찬가지로 나스닥 지수도 0.2% 상승하여 16,227.46으로 마감했다.
이들은 소매 트레이더들과 투자자들의 관심을 끈 주요 주식이다.
아마존 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)
아마존의 주식은 0.95% 상승하여 182.41달러에 마감했으며, 이 날의 최고가와 최저가는 각각 182.87달러와 179.8달러이다. 52주 신고가와 신저가는 각각 183달러와 97.71달러이며, BofA의 애널리스트 저스틴 포스트(Justin Post)는 스마트 카트와 자동화 물류 센터를 통해 성장할 것으로 예상하며 아마존에 대해 ‘매수&#8217; 평가를 재확인했다.
월트 디즈니 컴퍼니 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>)
디즈니의 주가는 3.13% 하락하여 118.98달러에 마감했으며, 이 날의 최고가와 최저가는 각각 123.69달러와 118.38달러이다. 52주 신고가와 신저가는 각각 123.74달러와 78.73달러이다. 디즈니는 연례 주주총회에서 <a href="https://www.benzinga.com/general/entertainment/24/04/38076617/disney-board-emerges-victorious-in-shareholder-vote-beats-trian-and-blackwells-nominees-sha">공동 경영 구조 제안을 반대했던 기관투자가들에게 압승을 거뒀다.</a>
참고: CHUCK Meme Coin That Aims To &#8216;Make Ethereum Great Again&#8217; Skyrockets 25,800% Hours After Launch, Leaving D
오로라 카나비스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>)
오로라 카나비스(Aurora Cannabis)의 주식은 44.06% 급등하여 7.21달러에 마감했으며, 이날의 최고가와 최저가는 각각 각각 7.39달러와 4.95달러이다. 52주 신고가와 신저가는 각각 11.5달러와 2.84달러이다. 카나비스 산업은 1분기에 스타일리시하게 마무리하며, 기존 투자자들의 상상력과 희망을 다시 일으켰다.
파라마운트 글로벌 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>)
파라마운트 글로벌(Paramount Global)의 주가는 14.97% 급등하여 13.52달러에 마감했으며, 이 날의 최고가와 최저가는 각각 13.8달러와 11.32달러이다. 52주 신고가와 신저가는 각각 24달러와 10.16달러이다. 미디어 자회사 스카이댄스 미디어(Skydance Media)와의 잠재적인 계약에 대한 논의가 뜨거워지자 시장의 <a href="https://www.benzinga.com/general/entertainment/24/04/38067898/paramount-skydance-deal-talks-fuel-investor-interest-but-charts-indicate-mixed-sentiments">관심이 집중되었다</a>
테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
테슬라의 주가는 1.05% 상승하여 168.38달러에 마감했으며, 이 날의 최고가와 최저가는 각각 168.82달러와 163.28달러이다. 52주 신고가와 신저가는 각각 299.29달러와 152.37달러이다. 회사는 이날 강한 배달 실적을 발표한 뒤로 테슬라 주식이 약세를 보이고 있다.
Shutterstock의 WHYFRAME 씨 촬영사진
벤징가 (Benzinga) 에 의한 상장 전 주요 움직임과 뉴스와 함께 오늘의 거래에 <a href="Premarket Movers &amp; News">준비하세요</a>.
다음 읽기: 제임크레이머, 테슬라의 강세에 대한 낙관적인 전망은?

Comments

Aurora Cannabis

뉴스

에 대한 최신 뉴스 Aurora Cannabis (NASDAQ:ACB) 주식

목요일, 4월 04, 2024

뉴스

파트너 / 기고자

벤징가 글로벌